论文部分内容阅读
目的：比较消化系统肿瘤患者血清ＣＡ５０和ＣＡ１９－９免疫放射分析（ＩＲＭＡ）的诊断价值，探讨ＣＡ５０和ＣＡ１９－９联合检测模式的合理性。方法：ＩＲＭＡ方法检测１４９例消化系统肿瘤患者与对照组血清ＣＡ５０和ＣＡ１９－９，比较分析２项检测结果的关系和临床诊断价值指标。结果：带瘤生存组血清ＣＡ５０和ＣＡ１９－９单独和联合检测的阳性率显著高于术后无瘤组和良性疾病组（Ｐ＜０００５），其中肝和胰腺肿瘤患者的阳性率最高。ＣＡ５０和ＣＡ１９－９单独和联合检测的阳性率差异在各组均无显著性（Ｐ均＞００５）。各组血清ＣＡ５０和ＣＡ１９－９的检测结果呈正相关（Ｐ＜００５）。结论：血清ＣＡ５０和ＣＡ１９－９均可用于消化系统肿瘤的诊断和病情监测。它们的ＩＲＭＡ结果存在正相关关系，联合检测的临床价值并不高于其中一项单独检测。
Objective: To compare the diagnostic value of serum CA50 and CA19-9 immuno-radiometric analysis (IRMA) in patients with digestive system tumors and to explore the rationality of the combined detection mode of CA50 and CA19-9. Methods: The serum levels of CA50 and CA19-9 in 149 patients with digestive system tumors and controls were detected by IRMA. The relationship between the two test results and the clinical diagnostic value were compared. Results: The positive rates of serum CA50 and CA19-9 alone and in combination with tumor-bearing survival group were significantly higher than those in the non-tumorous group and benign disease group (P <0005). The positive rates of liver cancer and pancreatic cancer patients were the highest. The positive rates of CA50 and CA19-9 alone and in combination were not significantly different in all groups (P> 0.05). The results of serum CA50 and CA19-9 in each group showed a positive correlation (P <005). Conclusion: Serum CA50 and CA19-9 can be used in the diagnosis of digestive system tumors and disease monitoring. Their IRMA results have a positive correlation, and the combined test does not have a higher clinical value than one of the separate tests.